Generex Biotechnology Corporation
GNBT · OTC
7/31/2020 | 7/31/2019 | 7/31/2018 | 7/31/2017 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | -0.00 | -0.00 |
| FCF Yield | -149.62% | -260.87% | -76.13% | -72.00% |
| EV / EBITDA | -0.61 | -6.50 | 0.44 | -0.18 |
| Quality | ||||
| ROIC | -88.91% | -207,102.57% | -4.82% | 62.30% |
| Gross Margin | 78.24% | 33.28% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.18 | 0.87 | -0.06 | 0.02 |
| Growth | ||||
| Revenue 3-Year CAGR | 55.83% | – | – | – |
| Free Cash Flow Growth | 38.06% | -329.70% | -96.67% | -50.92% |
| Safety | ||||
| Net Debt / EBITDA | -0.44 | -4.43 | 0.36 | -0.16 |
| Interest Coverage | -2.52 | -2,975.88 | -4.28 | -2.15 |
| Efficiency | ||||
| Inventory Turnover | 0.78 | 11.40 | 0.00 | 0.00 |
| Cash Conversion Cycle | -14,559.25 | -1,646.70 | 17.42 | 0.00 |